The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2024 | Bone disease in patients with thalassemia
In this video, Julian Waung, BM, PhD, Whittington Hospital, London, UK, provides insight into his talk on bone disease in beta-thalassemia, which included a case study of a male patient with thalassemia who had atypical femoral fracture. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, of course. So, the talk I gave had three main components. One was a framework to approach how to assess bone disease specific to people with beta thalassemia. The second part was using a case to illustrate some of those concepts and also explore some of the treatment choices and complications related to that and I chose a case that had a rare but really important complication called atypical femoral fracture which can occur in people who use bisphosphonates for a very long time...
Yeah, of course. So, the talk I gave had three main components. One was a framework to approach how to assess bone disease specific to people with beta thalassemia. The second part was using a case to illustrate some of those concepts and also explore some of the treatment choices and complications related to that and I chose a case that had a rare but really important complication called atypical femoral fracture which can occur in people who use bisphosphonates for a very long time. And then the final bit was then using that information to think about what are some of the inequalities or inequities that exist. So, in my particular case, in my patient, the fact that he was male, the fact that he was young, the fact that the bone quality doesn’t come out fully with the bone mineral density scan, those all meant that he couldn’t access treatment automatically because of funding restrictions. And then also, there’s a number of quite sophisticated investigation techniques for bone disease which aren’t available throughout the world and they’re very important in helping to understand the causes of bone disease in thalassemia and how to treat them.
Read more...
